Thus the mechanisms underlying the delay of TGFα-driven breast cancer development by the FGFR4 deficit may be related to metabolic activities of FGF21/19 that cause systemic metabolic programming that in turn impacts local metabolic, and therefore, cellular effects such as the decrease in mitoses (Figure 4). This evidence concerns the gene FGFR4 and breast carcinoma.